• About +
    • Our Story
    • Meet the Team
  • Inhaled Interferon β +
    • Our Programmes
    • Publications
  • Investors +
    • Share Price Information
    • Reports & Presentations
    • Investor News
    • Shareholder Information
    • AIM Rule 26
    • Corporate Governance
  • News +
    • Press Releases & Media
    • TR-1/Options Press Releases
  • Careers
  • Contact
  • About
  • Inhaled Interferon β
  • Investors
  • News
  • Careers
  • Contact
  • Our Story
  • Meet the Team
  • Our Programmes
  • Publications
  • Share Price Information
  • Reports & Presentations
  • Investor News
  • Shareholder Information
  • AIM Rule 26
  • Corporate Governance
  • Press Releases & Media
  • TR-1/Options Press Releases
← Back to Media

In the News

WebMD's John Whyte MD talks to Synairgen CEO Richard Marsden
28th December 2021
Synairgen founder Professor Sir Stephen Holgate talks to John Whyte MD of WebMD
28th December 2021
Synairgen presents data on antiviral activity of lead asset
8th December 2021
Synairgen 'delighted' to get green light for US government-sponsored Phase III trials, starting soon
20th October 2021
Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants
24th May 2021
  • Interferon Beta
  • Our Science
  • COVID-19
  • COPD
  • Asthma
  • Relevant Publications
  • About
  • Our Story
  • Team
  • Careers
  • Contact
  • Investors
  • Investors Overview
  • Performance
  • Reports & Presentations
  • Investor News
  • Analysts
  • Media
  • News
  • Resources
Cookie PolicyLegalPrivacy Policy
© Synairgen plc. All Rights ReservedRegistered in England and Wales No. 5233429 | Site by Ether